Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app help older hearts? chile trial aims to find out

NCT ID NCT07633392

Disease control Sponsor: University of Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests NeoMayor, a smartphone app that gives personalized advice on exercise, diet, sleep, and mood to improve heart health. Researchers will enroll 240 adults aged 55 to 75 in Chile who are at risk for heart problems. Participants use the app for 4 months, and some also get a wearable activity tracker, while a control group receives standard health information.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NeoMayor smartphone app with wearable activity tracker
What this could lead to
If it works, this could offer a simple, app-based way for older adults to improve their heart health through better lifestyle habits.
What could go wrong
This is an early-stage trial with only 240 participants, so results may not apply to everyone. The app relies on users sticking with it, and improvements may be small or short-lived.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age between 55 and 75 years * Able to read and understand written instructions * Ownership of a smartphone and ability to use it independently * Physically inactive, defined as performing less than 30 minutes of daily physical activity or less than 2,5 h a week. * Intermediate or high cardiovascular risk, defined as the presence of at least three of the following: Hypertension (history diagnosed by specialist or general practitioner or ≥ 140 mmHg systolic or ≥90 mm Hg diastolic blood pressure at baseline or current antihypertensive treatment);Diabetes Mellitus (history diagnosed by specialist or general practitioner or fasting blood glucose ≥126 mg/dL or current pharmacologic treatment);Obesity (BMI ≥30 kg/m²); Dyslipidaemia (history diagnosed by specialist or general practitioner or lipid-lowering drugs or baseline total cholesterol ≥ 200 mg/dL or LDL cholesterol ≥100 mg/dL). Exclusion Criteria * Dementia defined as a score in the MEFO \< 9 * Significant limitations for independent mobility, including use of assistive devices, frailty, gait instability, or lower-limb painful conditions limiting physical activity * Uncorrected hearing or visual impairment preventing adequate use of a smartphone * Chronic neurological, psychiatric, or psychological disorders without regular treatment or follow-up. * Present severe alcohol or illicit drug use. * Severe or terminal illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypertensive disorder inherited lipid metabolism disorder Motor Activity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood pressure Body mass index Cardiovascular health status Diet quality Fasting glucose LDL cholesterol Physical activity Sleep duration Smoking status Urinary albumin-to-creatinine ratio

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital clinico Universidad de Chile. Carlos Lorca Tobar 999

    Santiago, Independencia, 8380456, Chile

  • Hospital de Til til Daniel Moya #100

    Tiltil, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.